Physician profile
Robert Cucinotta
NPI 1083653380
$534.15
in general payments reported to CMS, 2019-2025
11 companies · $16.52 in 2025
The $16.52 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $234 · 2020: $35.11 · 2021: $156 · 2022: $13.72 · 2023: $21.94 · 2024: $56.04 · 2025: $16.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $94.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $94.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $121.75 | 2021 | |
| Janssen Pharmaceuticals, INC | $100.00 | 2019 | |
| Amarin Pharma, INC. | $90.86 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $58.16 | 2019-2024 | Entyvio |
| Gilead Sciences, INC. | $38.92 | 2020-2023 | |
| Abbvie INC. | $34.32 | 2021-2025 | |
| Boston Scientific Corporation | $24.39 | 2019 | |
| Ironwood Pharmaceuticals, INC | $18.13 | 2020 | |
| Genzyme Corporation | $17.00 | 2024 | |
| Medtronic, INC. | $16.90 | 2021 | |
| Axonics, INC. | $13.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Cucinotta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.